TY - JOUR T1 - Molecular Analysis of Xenograft Models of Human Cancer Cachexia - Possibilities for Therapeutic Intervention JF - Cancer Genomics - Proteomics JO - Cancer Genomics Proteomics SP - 223 LP - 231 VL - 4 IS - 3 AU - AXEL J. BAUMGARTEN AU - HEINZ-HERBERT FIEBIG AU - ANGELIKA M. BURGER Y1 - 2007/05/01 UR - http://cgp.iiarjournals.org/content/4/3/223.abstract N2 - Approximately 50% of all cancer patients develop cachexia, a paraneoplastic syndrome that is characterized by wasting of adipose tissue and skeletal muscle mass. Cytokines, including TNF-α, interleukins-1, -6, and interferon-γ are known mediators of the cachectic process. The latter however represent only one of many imbalanced systems in cancer cachexia. The aim of this study was to further delineate the pathogenesis of cachexia by molecular profiling. Human renal cancer xenografts that do and do not induce cachexia in mice were used as disease models. Cachexia-associated gene expression was studied on Human Genome U95 Affymetrix arrays and revealed several new genes such as TNF-α ligand superfamily protein, interferon-γ treatment inducible protein, and DKFZ5641I1922. The expression of the IL-8 gene was also elevated in cachexia inducing xenografts (CIX). At the protein level, TNF-α was found expressed only in CIX, whereas IL-1 and IL-6 were not cachexia specific. Levels of parathyroid hormone-related protein were elevated in CIX and accompanied by hypercalcemia. COX-2 and prostaglandin E2 were also found to be over expressed. By using the COX-2 inhibitors rofecoxib and nimesulide, we were able to delay tumor-mediated wasting in vivo. Overall, our results suggest that cachexia is a multigenetic disease that will require complex combinations of drugs for an effective therapeutic intervention. ER -